Team Nice Côte d’Azur will attend the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 15-16, a key gathering for global institutional investors and European life sciences executives.
Sana Bouyahia, Head of Project Development – Health & Sports, will represent the territory and be available for one-to-one meetings.
Make an appointment with Sana Bouyahia
The Côte d’Azur life sciences ecosystem has reached a level of maturity that warrants attention from the investment community. Several assets based in the region are approaching critical regulatory and commercial milestones.
Nicox is preparing its U.S. NDA submission for NCX 470, a novel glaucoma treatment, scheduled for summer 2026. The FDA provided positive pre-NDA feedback in February.
Caranx Medical, based in Nice and now integrated into Carvolix, secured the first FDA clearance worldwide for an AI-powered real-time guidance software in cardiac valve implantation. U.S. commercialization is underway, supported by Truffle Capital and Edwards Lifesciences.
DimiCare Biotech, a spinoff from Inserm, CNRS and Université Côte d’Azur, won the i-Lab 2025 national competition for its precision antibiotics platform targeting multi-drug resistant infections. The company is entering preclinical studies and planning a €3M fundraising round in 2026.
IHU RespirERA, a nationally designated institute of excellence in respiratory diseases, operates under INCa mandate and actively seeks international co-development partners.
Nucleate France UniCA, the only French branch of the Harvard-born biotech accelerator, continues to convert academic research into investable ventures through Université Côte d’Azur.
The ecosystem rests on clinical research infrastructure that is rapidly scaling. In late March 2026, Nice University Hospital and Centre Hospitalier de Cannes signed the founding convention of AZUR, a new territorial clinical research entity designed to increase the number of clinical trials across the region, coordinate studies between hospitals, and strengthen the scientific attractiveness of the Côte d’Azur. Led by Nice University Hospital as the anchor institution of the GHT 06, AZUR is set to expand to all public hospitals in the Alpes-Maritimes département.
This structural momentum is matched by the territory’s ability to attract private capital. Eurobiomed, the regional competitiveness cluster, mobilized €302M for its members in 2025, including €160M in private funding.
Nice University Hospital, with 920 annual publications, 28 active patents and 130,000 m² of research and clinical capacity following the Pasteur 2 extension, provides the translational foundation on which these ventures are built.
